ITGAX and neoplasm: Using a cDC1-targeted vaccine model, we have demonstrated that mice with active β-catenin in their DCs (CD11c-β-cateninactive mice) exhibited impaired cross-priming and memory responses of tumor antigen-specific CD8 T cells.